ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management

Area of Science:

• Cardiovascular Medicine
• Lipidology
• Clinical Biochemistry

Background:

• Current EAS/ESC and CCS guidelines maintain LDL-C as the primary target for lipid-lowering therapy.
• Non-HDL-C and apoB are considered secondary targets, with limited evidence presented for LDL-C's continued primary status.
• Guidelines suggest non-HDL-C and apoB are interchangeable, raising questions about their distinct roles.

Purpose of the Study:

• To differentiate LDL-C, non-HDL-C, and apoB, clarifying what each measures.
• To review evidence supporting LDL-C, non-HDL-C, and apoB as cardiovascular risk predictors and treatment targets.
• To emphasize the importance of diagnosing atherogenic dyslipoproteinemias as a clinical priority.

Main Methods:

• Comparative analysis of existing guidelines and scientific literature.
• Review of studies investigating the predictive value of LDL-C, non-HDL-C, and apoB for cardiovascular events.
• Examination of evidence regarding their efficacy as therapeutic targets.

Main Results:

• Clarification of distinct measurement properties of LDL-C, non-HDL-C, and apoB.
• Summary of evidence highlighting the roles of all three markers in cardiovascular risk prediction.
• Demonstration of the diagnostic utility of these markers for atherogenic dyslipoproteinemias.

Conclusions:

• LDL-C, non-HDL-C, and apoB possess unique characteristics and clinical applications.
• Evidence supports considering non-HDL-C and apoB alongside LDL-C in risk assessment and treatment.
• Diagnosis of specific atherogenic dyslipoproteinemias is crucial for effective patient management.